153 related articles for article (PubMed ID: 2049226)
1. DNA damage and cytotoxicity induced by metabolites of anthracycline antibiotics, doxorubicin and idarubicin.
Ferrazzi E; Woynarowski JM; Arakali A; Brenner DE; Beerman TA
Cancer Commun; 1991 Jun; 3(6):173-80. PubMed ID: 2049226
[TBL] [Abstract][Full Text] [Related]
2. Anthracyclines and their C-13 alcohol metabolites: growth inhibition and DNA damage following incubation with human tumor cells in culture.
Kuffel MJ; Reid JM; Ames MM
Cancer Chemother Pharmacol; 1992; 30(1):51-7. PubMed ID: 1586980
[TBL] [Abstract][Full Text] [Related]
3. Markedly reduced levels of anthracycline-induced DNA strand breaks in resistant P388 leukemia cells and isolated nuclei.
Capranico G; Riva A; Tinelli S; Dasdia T; Zunino F
Cancer Res; 1987 Jul; 47(14):3752-6. PubMed ID: 3474061
[TBL] [Abstract][Full Text] [Related]
4. Induction of DNA damage, inhibition of DNA synthesis and suppression of c-myc expression by the anthracycline analog, idarubicin (4-demethoxy-daunorubicin) in the MCF-7 breast tumor cell line.
Gewirtz DA; Randolph JK; Chawla J; Orr MS; Fornari FA
Cancer Chemother Pharmacol; 1998; 41(5):361-9. PubMed ID: 9523731
[TBL] [Abstract][Full Text] [Related]
5. Enhanced sensitivity of the rat hepatoma cell to the daunorubicin analogue 4-demethoxydaunorubicin associated with induction of DNA damage.
Woods KE; Ellis AL; Randolph JK; Gewirtz DA
Cancer Res; 1989 Sep; 49(17):4846-51. PubMed ID: 2758416
[TBL] [Abstract][Full Text] [Related]
6. Comparative resistance of idarubicin, doxorubicin and their C-13 alcohol metabolites in human MDR1 transfected NIH-3T3 cells.
Kuffel MJ; Ames MM
Cancer Chemother Pharmacol; 1995; 36(3):223-6. PubMed ID: 7781142
[TBL] [Abstract][Full Text] [Related]
7. Formation, resealing and persistence of DNA breaks produced by 4-demethoxydaunorubicin in P388 leukemia cells.
Capranico G; Tinelli S; Zunino F
Chem Biol Interact; 1989; 72(1-2):113-23. PubMed ID: 2555070
[TBL] [Abstract][Full Text] [Related]
8. Human DNA topoisomerase IIalpha-dependent DNA cleavage and yeast cell killing by anthracycline analogues.
Binaschi M; Farinosi R; Austin CA; Fisher LM; Zunino F; Capranico G
Cancer Res; 1998 May; 58(9):1886-92. PubMed ID: 9581829
[TBL] [Abstract][Full Text] [Related]
9. Differential single- versus double-strand DNA breakage produced by doxorubicin and its morpholinyl analogues.
Duran GE; Lau DH; Lewis AD; Kühl JS; Bämmler TK; Sikic BI
Cancer Chemother Pharmacol; 1996; 38(3):210-6. PubMed ID: 8646794
[TBL] [Abstract][Full Text] [Related]
10. Single-strand DNA breaks induced by chromophore-modified anthracyclines in P388 leukemia cells.
Capranico G; Soranzo C; Zunino F
Cancer Res; 1986 Nov; 46(11):5499-503. PubMed ID: 3463414
[TBL] [Abstract][Full Text] [Related]
11. Comparative activity of anthracycline 13-dihydrometabolites against rat glioblastoma cells in culture.
Schott B; Robert J
Biochem Pharmacol; 1989 Nov; 38(22):4069-74. PubMed ID: 2597184
[TBL] [Abstract][Full Text] [Related]
12. Phase I and II agents in cancer therapy: I. Anthracyclines and related compounds.
Wadler S; Fuks JZ; Wiernik PH
J Clin Pharmacol; 1986; 26(7):491-509. PubMed ID: 2944917
[TBL] [Abstract][Full Text] [Related]
13. Circumvention of resistance by doxorubicin, but not by idarubicin, in a human leukemia cell line containing an intercalator-resistant form of topoisomerase II: evidence for a non-topoisomerase II-mediated mechanism of doxorubicin cytotoxicity.
Zwelling LA; Bales E; Altschuler E; Mayes J
Biochem Pharmacol; 1993 Jan; 45(2):516-20. PubMed ID: 8382067
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the protective effects of quercetin, rutin, naringenin, resveratrol and trolox against idarubicin-induced DNA damage.
Celik H; Arinç E
J Pharm Pharm Sci; 2010; 13(2):231-41. PubMed ID: 20816008
[TBL] [Abstract][Full Text] [Related]
15. Comparative aneugenicity of doxorubicin and its derivative idarubicin using fluorescence in situ hybridization techniques.
Attia SM
Mutat Res; 2011 Oct; 715(1-2):79-87. PubMed ID: 21856314
[TBL] [Abstract][Full Text] [Related]
16. A comparison of the in vitro genotoxicity of anticancer drugs idarubicin and mitoxantrone.
Błasiak J; Gloc E; Warszawski M
Acta Biochim Pol; 2002; 49(1):145-55. PubMed ID: 12136935
[TBL] [Abstract][Full Text] [Related]
17. Comparative cardiotoxicity of idarubicin and doxorubicin using the isolated perfused rat heart model.
Platel D; Pouna P; Bonoron-Adèle S; Robert J
Anticancer Drugs; 1999 Aug; 10(7):671-6. PubMed ID: 10507317
[TBL] [Abstract][Full Text] [Related]
18. Can cytotoxic activity of anthracyclines be related to DNA damage?
Nishiyama M; Horichi N; Mazouzi Z; Bungo M; Saijo N; Tapiero H
Anticancer Drug Des; 1990 Feb; 5(1):135-9. PubMed ID: 2317255
[TBL] [Abstract][Full Text] [Related]
19. DNA topoisomerase II-mediated interaction of doxorubicin and daunorubicin congeners with DNA.
Bodley A; Liu LF; Israel M; Seshadri R; Koseki Y; Giuliani FC; Kirschenbaum S; Silber R; Potmesil M
Cancer Res; 1989 Nov; 49(21):5969-78. PubMed ID: 2551497
[TBL] [Abstract][Full Text] [Related]
20. Formation and longevity of idarubicin-induced DNA topoisomerase II cleavable complexes in K562 human leukaemia cells.
Willmore E; Errington F; Tilby MJ; Austin CA
Biochem Pharmacol; 2002 May; 63(10):1807-15. PubMed ID: 12034365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
